You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 22, 2025

CLINICAL TRIALS PROFILE FOR FLUOCINONIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Fluocinonide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00297011 ↗ Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis Completed GlaxoSmithKline Phase 2 2004-09-01 A randomized study comparing the combination of valacyclovir and temovate gel (clobetasol gel) versus placebo for the treatment of recurrent herpes labialis (cold sores).
NCT00297011 ↗ Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis Completed University of Utah Phase 2 2004-09-01 A randomized study comparing the combination of valacyclovir and temovate gel (clobetasol gel) versus placebo for the treatment of recurrent herpes labialis (cold sores).
NCT00667589 ↗ Sorafenib-induced Hand- Foot Skin Reaction Treatment Terminated Bayer Phase 2 2008-06-01 The purpose of this study is to evaluate treatments for a rash caused by sorafenib.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fluocinonide

Condition Name

Condition Name for Fluocinonide
Intervention Trials
Atopic Dermatitis 3
Breast Carcinoma 1
Hand-foot Skin Reaction 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fluocinonide
Intervention Trials
Eczema 3
Dermatitis, Atopic 3
Dermatitis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fluocinonide

Trials by Country

Trials by Country for Fluocinonide
Location Trials
United States 7
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fluocinonide
Location Trials
North Carolina 3
Oregon 2
Illinois 1
Utah 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fluocinonide

Clinical Trial Phase

Clinical Trial Phase for Fluocinonide
Clinical Trial Phase Trials
Phase 4 2
Phase 2 4
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fluocinonide
Clinical Trial Phase Trials
Completed 6
Recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fluocinonide

Sponsor Name

Sponsor Name for Fluocinonide
Sponsor Trials
Medicis Pharmaceutical Corporation 3
Wake Forest University 2
Wake Forest University Health Sciences need to be deleted 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fluocinonide
Sponsor Trials
Other 12
Industry 7
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for Fluocinonide

Introduction

Fluocinonide is a potent corticosteroid used in various medical applications, particularly for treating skin conditions and other inflammatory diseases. This article will delve into recent clinical trials, market analysis, and projections for fluocinonide, providing a comprehensive overview of its current and future standing.

Clinical Trials

Oral Lichen Planus

A notable clinical trial conducted by the University of Catania evaluated the efficacy of fluocinonide 0.05% oral gel in treating oral lichen planus. This double-blind, placebo-controlled study involved approximately 20 patients divided into two groups: one treated with fluocinonide 0.05% oral gel applied twice daily for one month, and a control group receiving a placebo. The study followed patients for two months to assess the clinical efficacy and statistical significance of the treatment outcomes[4].

Other Applications

While the specific trial mentioned above focuses on oral lichen planus, fluocinonide is commonly used in various dermatological conditions. For instance, a study on the combination of ciprofloxacin and fluocinolone (a related corticosteroid) showed that corticosteroids like fluocinonide can be effective in treating skin infections when used appropriately, although the study did not specifically use fluocinonide[1].

Market Analysis

Global Corticosteroids Market

The global corticosteroids market, which includes fluocinonide, is projected to grow at a Compound Annual Growth Rate (CAGR) of nearly 4.8% during the forecast period. This growth is driven by the increasing demand for topical and inhaled corticosteroids, particularly due to the rising prevalence of skin allergies and acute respiratory disorders[2].

Fluocinonide API Market

The fluocinonide Active Pharmaceutical Ingredient (API) market is a significant segment within the broader corticosteroids market. Key players such as Taro Pharmaceutical Industries, Farmabios SpA, and Tianjin Tianyao Pharmaceuticals are driving the market growth. The market can be segmented based on product types (purity above 99% and below 99%), major applications (creams and others), and important regions including North America, Europe, Asia Pacific, and South America[2].

Market Projections

Growth Drivers

The growth of the fluocinonide API market is primarily driven by the increasing demand for topical corticosteroids. Factors such as the rising prevalence of skin allergies, atopic dermatitis, and other inflammatory skin conditions contribute significantly to this demand. Additionally, advancements in pharmaceutical formulations and the expansion of healthcare infrastructure in emerging markets are expected to boost the market[2].

Regional Insights

The market is expected to see significant growth in regions such as North America, Europe, and the Asia Pacific. In North America, the high prevalence of skin allergies and the presence of well-established pharmaceutical companies are key drivers. In Europe, countries like Germany, France, and the UK are expected to contribute substantially to the market growth. The Asia Pacific region, particularly countries like China, Japan, and India, is anticipated to experience rapid growth due to increasing healthcare spending and a large patient population[2].

Competitive Landscape

The fluocinonide API market is competitive, with several key players vying for market share. Companies like Taro Pharmaceutical Industries, Farmabios SpA, and Tianjin Tianyao Pharmaceuticals are among the leading manufacturers. These companies are focusing on improving product purity, expanding their product portfolios, and enhancing their distribution networks to maintain their market positions[2].

Key Statistics and Insights

  • Market Size: The global corticosteroids market, which includes fluocinonide, was valued at a significant amount and is expected to grow at a CAGR of nearly 4.8% during the forecast period[2].
  • Prevalence of Skin Allergies: In 2018, the number of children under 18 years with reported skin allergies in the US was substantial, contributing to the increased demand for topical corticosteroids like fluocinonide[2].
  • Product Purity: The market is segmented based on product purity, with products having purity above 99% and below 99% catering to different needs and applications[2].

Clinical Efficacy Highlights

"A double-blind placebo-controlled study conducted to evaluate the clinical efficacy of Fluocinonide 0.05% oral gel showed promising results in treating oral lichen planus, highlighting the potential of fluocinonide in various dermatological applications"[4].

Key Takeaways

  • Clinical Trials: Fluocinonide has shown efficacy in treating oral lichen planus and other skin conditions, as evidenced by recent clinical trials.
  • Market Growth: The global corticosteroids market, including fluocinonide, is projected to grow at a CAGR of nearly 4.8% driven by increasing demand for topical and inhaled corticosteroids.
  • Regional Insights: North America, Europe, and the Asia Pacific are expected to be key regions driving market growth.
  • Competitive Landscape: The market is competitive with key players focusing on product purity, portfolio expansion, and distribution network enhancement.

FAQs

What is the current market size of the global corticosteroids market?

The global corticosteroids market, which includes fluocinonide, is estimated to grow at a CAGR of nearly 4.8% during the forecast period, but the exact current market size is not specified in the sources provided.

Which regions are expected to drive the growth of the fluocinonide API market?

North America, Europe, and the Asia Pacific are expected to be the key regions driving the growth of the fluocinonide API market.

What are the primary applications of fluocinonide?

Fluocinonide is primarily used in topical applications, such as creams, to treat various skin conditions including skin allergies, atopic dermatitis, and other inflammatory skin diseases.

Who are the key players in the fluocinonide API market?

Key players include Taro Pharmaceutical Industries, Farmabios SpA, and Tianjin Tianyao Pharmaceuticals.

What is the expected growth rate of the global corticosteroids market?

The global corticosteroids market is expected to grow at a CAGR of nearly 4.8% during the forecast period.

Sources

  1. JAMA Network Open: Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide...
  2. OpenPR: Fluocinonide API Market Size Is Booming Worldwide | Taro Pharmaceutical Industries, Farmabios SpA
  3. ClinicalTrials.gov: Clinical Development Protocol QBGJ398-301 A...
  4. Network of Care: Impact of Fluocinonide 0,05% in Oral Lichen Planus
  5. Market Research Reports: Global Fluocinonide API Market Research Report 2024 | Market ...
Last updated: 2025-01-01

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.